首页> 外文期刊>Clinical drug investigation >A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer's Disease: Two Phase I Studies in Healthy Volunteers
【24h】

A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer's Disease: Two Phase I Studies in Healthy Volunteers

机译:美金刚缓释和多奈哌齐的新型每日一次固定剂量组合治疗中度至重度阿尔茨海默氏病:健康志愿者的两项I期研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background Combining two standard-of-care medications for Alzheimer's disease (AD) into a single once-daily dosage unit may improve treatment adherence, facilitate drug administration, and reduce caregiver burden. A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil was evaluated for bioequivalence with co-administered commercially available memantine ER and donepezil, and for bioavailability with regard to food intake.
机译:背景技术将两种用于阿尔茨海默氏病(AD)的护理标准药物合并到一个单一的每日一次剂量单位中,可以改善治疗依从性,促进药物管理并减轻护理人员的负担。评价了含有28 mg美金刚缓释(ER)和10 mg多奈哌齐的新固定剂量组合(FDC)胶囊与市售美金刚ER和多奈哌齐的共同生物等效性,以及食物摄入的生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号